Humacyte, Inc. SEC Filings

Humacyte, Inc. reported that director John Philip Bamforth received a grant of stock options covering 80,000 shares of common stock. The options have an exercise price of $1.08 per share and expire on June 11, 2036. Following this grant, he holds 80,000 options directly.

The footnote explains that 25% of the options become exercisable on June 11, 2027, with the remaining portion vesting in equal monthly installments (1/48 of the grant) on the 11th of each month through June 11, 2030. This is a compensation-related award rather than an open-market purchase.

Humacyte, Inc. director Emery N. Brown received a grant of stock options covering 80,000 shares of common stock at an exercise price of 1.08 per share. The options expire on June 11, 2036. One quarter vests on June 11, 2027, with the remainder vesting monthly through June 11, 2030.

Humacyte, Inc. director Brady W. Dougan received a grant of stock options to acquire common shares. The award covers options exercisable for 80,000 shares of Humacyte common stock at an exercise price of $1.08 per share, expiring on June 11, 2036.

The options were granted as compensation and do not reflect an open-market purchase or sale. According to the vesting terms, 25% of the options become exercisable on June 11, 2027, with the remaining options vesting in equal monthly installments through June 11, 2030.

Humacyte, Inc. entered into an underwriting agreement for a public offering of its common stock. The company is issuing 47,619,048 shares at a public offering price of $1.05 per share, with underwriters holding a 30‑day option to buy up to 7,142,857 additional shares.

Gross proceeds are expected to be $50 million, with net proceeds of about $46.80 million, or $53.85 million if the option is fully exercised. Humacyte plans to use the cash to commercialize its Symvess product, support a planned Biologics License Application supplement in a hemodialysis indication, advance its pipeline, and for working capital and general corporate purposes.

Humacyte, Inc. is offering 47,619,048 shares of its common stock pursuant to this prospectus supplement, at a public offering price of $1.05 per share (underwriters have a 30‑day option to purchase an additional 7,142,857 shares). The offering's gross proceeds are stated as $50,000,000.40, with estimated net proceeds to the company of approximately $47.0 million before expenses (approximately $53.85 million if the underwriters fully exercise their option).

The company reports that shares outstanding after the offering would be 269,638,156 (or 276,781,013 if the option is fully exercised). The prospectus supplement also discloses recently announced positive top-line interim results from the V012 Phase 3 trial, meeting its primary endpoint, and states an intention to submit a supplemental BLA in the second half of 2026. The company notes substantial doubt about its ability to continue as a going concern absent additional financing.

Humacyte, Inc. filed a preliminary prospectus supplement to offer shares of common stock (number and price not specified in the excerpt) and granted underwriters a 30-day option to purchase additional shares. Net proceeds are intended to fund Symvess commercialization, a planned supplemental BLA filing for hemodialysis, pipeline development and working capital.

The supplement also discloses positive top-line interim results from the V012 Phase 3 trial: ATEV patients averaged 220 catheter-free days versus 129 for AV fistula (p=0.00070), with infection rates of 6 vs. 23 per 100 patient-years. The company plans a supplemental BLA submission in the second half of 2026. Management reports available cash and equity capacity that fund operations into the first quarter of 2027 but states there is substantial doubt about its ability to continue as a going concern without additional financing.

Humacyte, Inc. reported positive interim Phase 3 results for its acellular tissue engineered vessel (ATEV) in female dialysis patients. In the V012 study’s prespecified analysis of the first 80 patients, ATEV met the primary endpoint, delivering an average of 91 more catheter-free days than autologous arteriovenous fistula, the current standard of care.

ATEV patients achieved 220 catheter-free days versus 129 with fistula (p=0.00070) and showed substantially lower infection rates. Based on these results, enrollment will stop and follow-up will continue, and Humacyte plans to file a supplemental Biologic License Application with the FDA in the second half of 2026 for high-risk end-stage kidney disease patients.

Humacyte, Inc. reported results of its 2026 Annual Meeting of Stockholders held on June 9, 2026. Stockholders approved an amendment to the Certificate of Incorporation increasing authorized common shares from 350,000,000 to 550,000,000, which became effective upon filing in Delaware on June 9, 2026.

As of the April 23, 2026 record date, 222,019,108 common shares were outstanding, and 127,474,086 shares, or about 57.41%, were represented to form a quorum. Stockholders elected three Class II directors, approved on an advisory basis the compensation of named executive officers and chose to hold future say-on-pay votes annually.

They also ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026 and formally approved the increase in authorized common stock. No broker non-votes were recorded on the auditor ratification or share authorization proposals.

Humacyte, Inc. has regained compliance with Nasdaq’s minimum bid price rule. The company had previously been notified that its common stock traded below the required $1.00 per share bid price for 30 consecutive business days ended May 1, 2026.

To cure the issue, Humacyte’s stock needed to close at or above $1.00 for at least 10 consecutive business days before November 2, 2026. On June 5, 2026, Nasdaq informed the company that this condition was met and that its listing on The Nasdaq Global Select Market is now in good standing, with the matter considered closed.